Results 171 to 180 of about 120,862 (212)
Correction: Cancer-associated adipocyte promote progression and immunosuppression in triple-negative breast cancer. [PDF]
Front OncolZhang X +5 more
europepmc +1 more source
Triple-Negative Breast Cancer [PDF]
New England Journal of Medicine, 2010 Recent advances in biological characterization of breast cancer have eventually increased our understanding of underlying tumour biology. While for endocrine responsive and Her2-positive disease different molecular targeted therapies are available, up to now no specific targeted approach for triple-negative breast cancer has been developed.
William Foulkes +2 more
exaly +11 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pathogenesis of Triple-Negative Breast Cancer
Annual Review of Pathology: Mechanisms of Disease, 2022Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of fundamentally different diseases with different histologic, genomic, and immunologic profiles, which are aggregated under this term because of their lack of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression.
Fatemeh Derakhshan, Jorge Reis-Filho
exaly +3 more sources
Current Opinion in Oncology, 2008
Triple-negative breast cancer has been of great interest to oncologists because these cancers do not benefit from hormonal therapies or treatments targeted against human epidermal growth factor receptor 2 receptors. The only systemic therapy currently available is chemotherapy, and prognosis remains poor.
Gert, Stockmans +4 more
openaire +4 more sources
Triple-negative breast cancer has been of great interest to oncologists because these cancers do not benefit from hormonal therapies or treatments targeted against human epidermal growth factor receptor 2 receptors. The only systemic therapy currently available is chemotherapy, and prognosis remains poor.
Gert, Stockmans +4 more
openaire +4 more sources
Immunotherapy in Triple-Negative Breast Cancer
The Cancer Journal, 2021Abstract Triple-negative breast cancer (TNBC) is an aggressive subtype of mammary carcinoma. A subset of TNBC is immune activated, suggesting that immunotherapy may be a viable treatment strategy. Phase III clinical trials have shown that atezolizumab or pembrolizumab is well-tolerated in combination with chemotherapy, with progression-free ...
openaire +2 more sources
An overview of triple-negative breast cancer
Archives of Gynecology and Obstetrics, 2015Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors comprising various breast cancers simply defined by the absence of estrogen receptor, progesterone receptor and overexpression of human epidermal growth factor receptor 2 gene.
Pankaj Kumar, Rupali Aggarwal
openaire +2 more sources
Metastatic Triple-negative Breast Cancer
Clinical Oncology, 2011The triple-negative class (oestrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) comprises about 15% of breast cancer. It is associated with a poor prognosis compared with tumours that are positive for hormone receptors or HER2.
E A, Rakha, S, Chan
openaire +2 more sources